Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Centre For Immunology & Infection Limted manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This action is assigned to 1 distinct examiner, SEAN JAMES STEINKE. The prosecution is located within 1 distinct art unit, which indicates a specialized focus for the company's immunological research. This concentration ensures that the 1 pending office action is reviewed by an examiner with specific expertise in infection-related technologies.
SEAN JAMES STEINKE is the busiest examiner for the company, currently managing 1 pending office action. This examiner is responsible for all pending office actions in the current data set. With 1 distinct examiner and 1 distinct art unit, the prosecution process is highly concentrated. The 1 pending office action represents the total active engagement with the patent office for this portfolio. This centralized approach means that the company's current patent prospects are focused on the evaluation of 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEINKE, SEAN JAMES | 1 | 12.5% | +42.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18182237 | COPPER FILTER WITH FAST VIRUS KILLING ABILITY | STEINKE, SEAN JAMES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18182237 | COPPER FILTER WITH FAST VIRUS KILLING ABILITY | STEINKE, SEAN JAMES | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18182237 | COPPER FILTER WITH FAST VIRUS KILLING ABILITY | STEINKE, SEAN JAMES | 1619 | §103§112 | Non-Final OA | — | Pending | Mar 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentre For Immunology & Infection Limted has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sean James Steinke has the most, with 1 of Centre For Immunology & Infection Limted's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
